Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

Cory Mavis, Kevin Zablonski, Suchitra Sundaram, Juan Gu, Pallawi Torka, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 12357–12358.

https://doi.org/10.1182/blood-2022-169123

Published: 2022

Journal Articles

Clinical Impact of the Intensity of Induction Regimens Prior to Consolidation in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma (PTCL)

Muhammad Salman Faisal, Gabrielle Hartman, Arya Roy, Andrea Anampa-Guzman, Sheeba Ba Aqeel, Hassan Awada, Matthew J Cortese, Pallawi Torka, Suchitra Sundaram, Paola Ghione

Blood (2022) 140 (Supplement 1): 6573–6574.

https://doi.org/10.1182/blood-2022-169156

Published: 2022

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

https://doi.org/10.1182/blood-2022-157105

Published: 2022

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

Blood (2021) 138 (Supplement 1): 455.

https://doi.org/10.1182/blood-2021-144308

Published: 2021

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 391.

https://doi.org/10.1182/blood-2021-147599

Published: 2021

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 381.

https://doi.org/10.1182/blood-2021-149138

Published: 2021

Journal Articles

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy

Blood (2021) 138 (Supplement 1): 184.

https://doi.org/10.1182/blood-2021-146398

Published: 2021

Journal Articles

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

Shipra Goel, Juan J. Gu, Pallawi Torka, Cory Mavis, Suchitra Sundaram, Mirdza Neiders, Lakshmanan Suresh, Long Shen, Vince Ramsperger, Elizabeth A. Griffiths, Brahm Segal, Francisco J. Hernandez-Ilizaliturri, Paola Ghione

Blood (2021) 138 (Supplement 1): 1340.

https://doi.org/10.1182/blood-2021-152738

Published: 2021

Journal Articles

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

Swaminathan P Iyer, Auris Huen, Weiyun Z. Ai, Deepa Jagadeesh, Mary Jo Lechowicz, Craig Okada, Tatyana A. Feldman, Suchitra Sundaram, Juan Pablo Alderuccio, Nishitha Reddy, Don Stevens, Timothy M. Kuzel, Ann Mohrbacher, Kasi Viswanath Routhu, Prajak Barde, Ajit Mohanchandran Nair, Brad M. Haverkos

Blood (2021) 138 (Supplement 1): 1365.

https://doi.org/10.1182/blood-2021-145851

Published: 2021

Journal Articles

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander R. Coltoff, Matthew S. Davids, Peter O. Baker, Lori Leslie, Kerry A. Rogers, John N. Allan, Raul Cordoba, Alberto Lopez-Garcia, Darko Antic, John M. Pagel, Nicolas Martinez-Calle, José Antonio García-Marco, Jose‐Ángel Hernández‐Rivas, Fatima Miras, Catherine C. Coombs, Anders Österborg, Lotta Hansson, Amanda N. Seddon, Javier López Jiménez, Matthew R. Wilson, Dima El-Sharkawi, Daniel Wojenski, Shuo Ma, Talha Munir, Susana Valenciano, Erlene Seymour, Paul M. Barr, Jeffrey Pu, Piers E. M. Patten, Guilherme F. Perini, Scott F. Huntington, Helen Parry, Suchitra Sundaram, Alan Skarbnik, Manali Kamdar, Ryan Jacobs, Harriet Walter, Renata Walewska, Angus Broom, Sonia Lebowitz, Krista M. Isaac, Craig A. Portell, Inhye E. Ahn, Chaitra S. Ujjani, Mazyar Shadman, Sigrid S. Skånland, Elise A. Chong, Anthony R. Mato

Blood (2021) 138 (18): 1768–1773.

https://doi.org/10.1182/blood.2021011841

Published: 2021

Includes: Supplemental data

Journal Articles

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Blood (2021) 138 (9): 811–814.

https://doi.org/10.1182/blood.2021012443

Published: 2021

Includes: Supplemental data

Journal Articles

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Blood (2021) 137 (3): 374–386.

https://doi.org/10.1182/blood.2020006926

Published: 2021

Includes: Supplemental data

Journal Articles

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Swami P. Iyer, MD, Auris Huen, MD, Bradley Haverkos, MD MPH, MS, Weiyun Z. Ai, Craig Okada, MD PhD, Timothy M. Kuzel, MD, Mary Jo Lechowicz, MD, Juan Pablo Alderuccio, MD, Ann Mohrbacher, MD, Don A. Stevens, MD, Ryan A. Wilcox, MD, Tatyana A. Feldman, MD, Suchitra Sundaram, MD, Deepa Jagadeesh, MDMPH, Nishitha Reddy, MD MSCI, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-136018

Published: 2020

Journal Articles

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Juan J Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137812

Published: 2020

Journal Articles

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Suchitra Sundaram, MD, Cory Mavis, MSc, Juan J Gu, PhD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143237

Published: 2020

Journal Articles

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Prashasti Agrawal, Kevin A. David, MD, Zhengming Chen, PhD MPH, MS, Suchitra Sundaram, MD, Seo-Hyun Kim, MD, Ryan Vaca, MD, Yong Lin, PhD, Samuel Singer, MD, Mary-Kate Malecek, MD, Jordan Carter, MD, Adam Zayac, MD, Myung Sun Kim, MD, Nishitha Reddy, MD, Alma Habib, MD, Christopher Strouse, MD, Jerome Graber, MD, Veronika Bachanova, MD PhD, Mazie Tsang, MD, Ajay Major, MDMBA, David A. Bond, MD, Angel Mier-Hicks, MD, Pallawi Torka, MD, Priya Rajakumar, MD, Parameswaran Venugopal, MD, Michael Glantz, MD PhD, Samuel Goldlust, MD, Rahul Matnani, MD, Pallavi Kumar, MD, Thomas A Ollila, MD, Johnny Cai, DO, Stephen E. Spurgeon, MD, Alex G Sieg, MD MS, Joseph Cleveland, MD, Narendranath Epperla, MDMS, Reem Karmali, MDMSc, Seema Naik, MD, Sonali M. Smith, MD, James L. Rubenstein, MD PhD, Brad S. Kahl, MD, Amy Chadburn, MD, Andrew M. Evens, DO,MMSc, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-138885

Published: 2020

Journal Articles

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-136551

Published: 2020

Journal Articles

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Adam J Olszewski, MD, Lasse H. Jakobsen, PhD, Graham P. Collins, MD DPhil, Kate Cwynarski, Veronika Bachanova, MD PhD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Mark Bower, MD, Alessia Dalla Pria, MD, Alexey Danilov, MD, Kevin A. David, MD, Catherine Diefenbach, MD, Fredrik Ellin, MD PhD, Narendranath Epperla, MDMS, Umar Farooq, MD, Tatyana A. Feldman, MD, Alina S. Gerrie, MD MPH, Deepa Jagadeesh, MDMPH, Manali Kamdar, MD MD, Reem Karmali, MDMSc, Shireen Kassam, MBBS, FRCPath, PhD, Vaishalee P. Kenkre, MD, Nadia Khan, MD, Andreas Klein, MD, Izidore S. Lossos, MD, Matthew A. Lunning, DO, FACP, Peter Martin, FRCPC, MD MS, Nicolas Martinex-Calle, Silvia Montoto, MD, Seema Naik, MD, Neil Palmisiano, MDMS, David Peace, MD, Elizabeth H Phillips, MBBS, BSc, Tycel J. Phillips, MD, Craig A. Portell, MD, Nishitha Reddy, MD, Anna Santarsieri, MBBS, Maryam Sarraf Yazdy, MD, Knut B. Smeland, Scott E. Smith, MD PhD, Stephen D. Smith, MD, Suchitra Sundaram, MD, Parameswaran Venugopal, MD, Adam Zayac, MD, Xiao-Yin Zhang, PhD, Catherine Zhu, Chan Yoon Cheah, MBBS, Tarec Christoffer El-Galaly, Andrew M. Evens, DO,MMSc

Blood (2020) 136 (Supplement 1): 46–49.

https://doi.org/10.1182/blood-2020-134985

Published: 2020

NARROW

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

Clinical Impact of the Intensity of Induction Regimens Prior to Consolidation in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma (PTCL)

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only